“We Use the Method™”: How to Charge €400/hr for a Matrix and Get Away With It
Strategy was once a noun. Then someone turned it into a 2x2 matrix and started charging €400/hour for it.
The Rise and Fall of bluebird bio: A Gene Therapy Pioneer’s Journey
Foundations of a Gene Therapy Pioneer (1992–2010)
bluebird bio began not as the vibrant name suggests, but as a
Advisers Advise, Ministers Decide: A Founder’s Manifesto
In the spirit of Thatcher—and with apologies to everyone who just spat out their ethically sourced oat milk—here’
Royalty Financing in Biotech: Trends, Insights, and Strategic Opportunities
The biotechnology sector continuously faces significant funding challenges, balancing the enormous costs of clinical development with the necessity of minimizing
Snake Oil in a Bottle: A Guide to Spotting Misleading Claims in Supplements and Therapies
If there’s one thing that consistently frustrates me, it’s how pseudoscientific claims are dressed up as life-saving innovations.
China’s Biotech Startups: Between Hype and Hard Truths
Conflicting Narratives in a Growing Sector
China’s early-stage biotech and drug development startups have been riding a seesaw of
Biotech IPOs: A Tale of Two Continents
Biotech IPOs: A Tale of Two Continents
Not long ago, biotech firms queued eagerly for public markets, buoyed by cheap
Don’t Bet on PME: A Tale of Public Market Equivalents and Their Limitations
You’re sitting across from a General Partner (GP) at a biotech-focused venture capital (VC) fund. They’re presenting their
Biotech Venture Capital’s Hard Reset
The global biotech venture capital boom of the late 2010s has decisively given way to a sobering downturn. After a
Real-World Evidence (RWE): A Detailed Examination of Its Role in Modern Healthcare
Real-World Evidence (RWE) has become one of the most discussed innovations in healthcare decision-making, promising to bridge the gap between
